Called AFM24, it targets a “warhead” commonly produced by a variety of cancers including lung, bowel, kidney, stomach and pancreatic.
An international study evaluated this therapy in a small trial of 24 patients. One-third responded well, including two whose tumors shrunk or stopped growing for more than three months.
Professor Kristian Helin, executive director of the Institute of Cancer Research, said: “So far, we have only seen initial findings in a small group of patients, but the results look promising and we optimistic that this could be a new type of immunotherapy for hard-to-treat cancers. ”
AFM24 is similar to advanced CAR-T therapy, in which the patient’s own immune cells are reprogrammed to target cancer. But while CAR-T is personalized, the new method could be cheaper, faster, and work against a wider range of cancers.
Source: | This article first appeared on Express.co.uk